Jump to content

PYC - PYC THERAPEUTICS LIMITED


ShareCafe

Recommended Posts

In reply to: Thompsjz69 on Sunday 06/05/07 10:15am

thompsjz69 fair comment--with the library pyc has why not a $1billion. http://www.sharescene.com/html/emoticons/icon14.gif

i certainly hope it keeps going north.pyc was once so loved http://www.sharescene.com/html/emoticons/wub.gif

Link to comment
Share on other sites

  • Replies 1.5k
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

In reply to: cobra on Sunday 06/05/07 08:09pm

1 Billion isn't out of the question, so fingers crossed, they did have a grand debut last year.

I've always treated htis stock as a bottom drawer set and forget for down the track, hopefully we're headed down that path sooner rather than later.

Good prospects, just need to get them to fruition. Lets see what the week brings.

Link to comment
Share on other sites

In reply to: Thompsjz69 on Sunday 06/05/07 09:33pm

 

Thompsjz69 report says if I;am not mistaken

 

"peptide pyc36s is for strpeptide pyc36s is for stroke, this is now/ nearly ready for a company to take it to the next stage. The company that takes pyc36s has to purchase it and pay royalties !!

I wonder if a partner is lined up.Yeap,will be interesting week http://www.sharescene.com/html/emoticons/ph34r.gif

Link to comment
Share on other sites

In reply to: cobra on Monday 07/05/07 09:08am

QUOTE
I wonder if a partner is lined up.

 

Which is why an ex-Pfizer man has joined the board.

 

The big question is Citi's 10%. A blocking stake or just sound investment?

Link to comment
Share on other sites

In reply to: crookers on Saturday 05/05/07 08:40pm

In addition to what Cobra has posted,PYC is focussed on the early stage of drug discovery.Once the drug is validated in pre-clinical studies it is then licensed to Big Pharma,in return (hopefully) for substantial up-front and milestone payments and royalty payments on sales,should it get that far.

Big Pharma is then responsible for financing the clinical trials to get the drug registered and approved by the various Regulatory Authorities so that it can "get to market" and benefit all concerned.

 

BTW that Market cap. is now around $52,000,000................nice opening to the week.

 

Cheers.

Link to comment
Share on other sites

Announcement out however SP down http://www.sharescene.com/html/emoticons/icon14.gif

 

 

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“These results are very encouraging and beyond our initial expectations. We are very pleased with the number and quality of drug candidates identified and confident to now move to the next stage of our collaboration with Phylogica," said Dr Mark Heffernan CEO Opsona Therapeutics.

 

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“This success with Opsona has put us at the cutting edge of TLR drug discovery, and has attracted the interest of major pharmaceutical companies that will lead to further deals in the near future, ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ said Dr Stewart Washer CEO Phylogica.

 

Wait and see what happens http://www.sharescene.com/html/emoticons/ohmy.gif

 

 

 

Link to comment
Share on other sites

In reply to: cobra on Monday 07/05/07 11:36am

Yes,very encouraging,particularly in the area of inflamatory disease.

As for the share price,early days,probably pulled back on some profit-taking.

----------------------------------------------------

Phylogica delivers on milestone with Opsona

11:24, Monday, 7 May 2007

 

Sydney - Monday - May 7: (RWE Aust Business News) - Phylogica

(ASX:PYC) has delivered on a major milestone with partner Opsona

Therapeutics.

Phylogica's collaborative agreement was formed to test its

Phylomer peptides and identify which could be used as drug candidates for

inflamatory disease.

The Phylomer drug candidates were tested in human cell assays and

actively blocked a pivotal pathway underlying the inflammatory response

in cells.

Further testing is now underway to select the most promising

candidates for further drug development and commercialisation for

inflammatory disease.

Opsona and Phylogica will expand the collaborative project to

other targets and are in discussions with major companies to

commercialise Phylomer candidates.

Phylogical shares were up 1c to 40.5c.

ENDS

 

 

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...